Mas­ter deal­mak­er? Medi­va­tion CEO David Hung’s overzeal­ous PARP as­sault falls flat

Medi­va­tion doesn’t look any fur­ther ahead now that the CEO is pub­licly de­fend­ing the as­set like a dog de­fends a bone

John Car­roll, Ed­i­tor

Back when David Hung was build­ing Medi­va­tion as a pipeline com­pa­ny, he per­suad­ed Pfiz­er to fork over $225 mil­lion as an up­front to part­ner on dime­bon, a Russ­ian an­ti­his­t­a­mine that had shown some ac­tiv­i­ty for Alzheimer’s in ear­ly stud­ies. Dime­bon went on to be­come an em­bar­rass­ing fi­as­co, fail­ing two ex­pen­sive Phase III stud­ies. And I can re­call Hung dis­count­ing the sig­nif­i­cance of the pro­gram to his com­pa­ny when he was be­tween late-stage flops. Af­ter all, he told me, Pfiz­er had paid for that work al­ready.

Hung and Medi­va­tion went on to glo­ry with Xtan­di, and the CEO clear­ly nev­er lost the abil­i­ty to tout ear­ly da­ta and look for an edge wher­ev­er he can find it. He is wide­ly re­gard­ed as one of the best deal­mak­ers in the busi­ness, and now that he’s bar­gain­ing over the sale of his com­pa­ny with Sanofi and like­ly Pfiz­er, Cel­gene and oth­ers, he’s pulling out all the stops to go for the high­est pos­si­ble price he can get – and then some.

That win-at-all-costs men­tal­i­ty was on dis­play Wednes­day evening, as Hung went to work on the one as­set he has with a wild­ly un­cer­tain val­ue: Medi­va­tion’s PARP in­hibitor ta­la­zoparib. Tak­ing a frag­ment of da­ta, he claimed that ta­la­zoparib was clear­ly the best of four con­tenders, far sur­pass­ing Tesaro’s ni­ra­parib, As­traZeneca’s Lyn­parza (ola­parib) and Ab­b­Vie’s veli­parib.

Ta­la­zoparib, he told an­a­lysts on a call, is a “multi­bil­lion-dol­lar op­por­tu­ni­ty.”

The drug, he ex­plained, is a PARP trap­per, far bet­ter at de­stroy­ing can­cer cells that an enyzme in­hibitor. There was more. Lots more. And he went far be­yond the com­pa­ny’s first stab at high­light­ing the drug’s spe­cial po­ten­tial.

David Hung, Medi­va­tion CEO

The oth­er drugs failed to mea­sure up, he said. There were safe­ty is­sues and so on. He said every­thing pos­si­ble that could build up the val­ue of ta­la­zoparib as the “best-in-class” op­por­tu­ni­ty in a de­vel­op­ing $30 bil­lion mar­ket. And he made a short at­tack on the com­pe­ti­tion as sor­ry, sec­ond-raters.

Here’s the full Pow­er­Point pre­sen­ta­tion.

Bot­tom line: If Sanofi ex­ecs think they can get that drug for a $3 CVR, they have to be dream­ing.

Medi­va­tion got this drug just a year ago, pay­ing out $410 mil­lion up­front. That’s a sig­nif­i­cant amount, and it suc­cess­ful­ly fo­cused a lot of at­ten­tion as the top prospect in the clin­ic. It cer­tain­ly war­rants more than the pass­ing men­tion re­served for pidilizum­ab, the PD-1 drug that em­bar­rass­ing­ly proved not to be a PD-1 drug. The FDA tem­porar­i­ly halt­ed work on a tri­al so reg­u­la­tors could get a bet­ter fix on the drug. (Medi­va­tion’s at­ti­tude: Hey, it works some­how, so it’s im­por­tant.)

The CEO is in the fight of his pro­fes­sion­al ca­reer. With the com­pa­ny in play, the best out­come for Hung here is that some­body pays a record price for his as­sets. And he’ll say any­thing to make that hap­pen.

The PARP war, though, is far from over. Medi­va­tion’s stock is up just a few cents this morn­ing. These bid­ders can as­sess the val­ue of a Phase III prospect as well as any­one. And Medi­va­tion doesn’t look any fur­ther ahead now that the CEO is pub­licly de­fend­ing the as­set like a dog de­fends a bone. If any­thing, he may have dam­aged his case by go­ing over­board on the zeal­ous as­sault.

— John Car­roll @John­Cendpts

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot the clinical and manufacturing bills.

Its heavyweight partners at Merck — which signed a pact around a mysterious “blockbuster indication” last month — jumped into the Series D, led by new investors Farallon Capital and Hadean Ventures. Adjuvant Capital also joined, as did current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.